Nav: Home

Genetic fixer-uppers may help predict bladder cancer prognosis

May 15, 2018

HERSHEY, Pa. -- Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers.

The researchers found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Dr. Monika Joshi, assistant professor of medicine, Penn State Cancer Institute, said that as researchers try to design better treatments for cancer patients, it's important for them to find biomarkers that can help researchers understand the differences between patients and their prognoses.

"We're coming to realize that not every cancer patient is the same," Joshi said. "We see some patients responding to therapies, while others do not. Treatments like chemotherapy and immunotherapy, do not have a 100 percent response rate. So we're trying to delve deeper to better understand biological differences between patients."

According to the researchers, mutations or defects in DNA repair genes -- like ATM and RB1 -- play a role in tumor growth and how the cancer responds to treatment, and are often found in patients with bladder cancer.

Previous research has also shown a connection between these mutated DNA repair genes and patients who respond better to certain types of chemotherapy. Joshi said this could be because the drug used in the treatment works better in cells when they're dividing.

"These genes help repair damage to the DNA, but when these genes are mutated, they actually reduce the repair response, allowing tumor cells with defective DNA to proliferate," Joshi said. "And when those tumor cells are proliferating, at that point they may be more susceptible to certain treatments like chemotherapy."

Joshi and the other researchers wanted to better examine how ATM and RB1 genes predicted the outcomes of patients with bladder cancer and analyzed information from two separate data sets.

The first or "discovery" data set included information about 130 bladder cancer patients from the Cancer Genome Atlas, a public database of cancer and genomic data. The second or "validation" data set included information about 81 patients with bladder cancer or other related cancers from three academic medical centers.

Mutations in the ATM or RB1 genes were found in 24 percent of patients in the discovery data set, and 22.2 percent of patients in the validation data set. Patients in both data sets with these mutations also tended not to live as long.

After two years, a significant difference was observed in the discovery data set in which about 15 percent of patients with mutations were still alive as compared to 45 percent of patients without mutations. A similar (although non-statistically significant) trend was noted in the validation data set, where about 50 percent of patients with mutations were still alive as opposed to 60 percent of patients without mutations.

Joshi said the results -- recently published in the journal Oncotarget -- bring up interesting questions when compared with the findings of previous studies.

"It would be interesting to further study these two specific genes and see what about them may make patients fare worse," Joshi said.

While it may be discouraging for patients to discover they have a gene that may predict a poor prognosis, Joshi added that the findings also have the potential to help researchers decide where to focus their work in the future.

"If we know patients with this gene have a poorer prognosis, we can focus our efforts to learn more about why this might be happening so we can improve therapies for these patients," Joshi said. "We might not have all the answers after this study, but I think it helps pave the way for future development of targeted therapies in bladder cancer."
-end-
Ming Yin, Monali Vasekar and Joseph J. Drabick, all of the Penn State Cancer Institute; Petros Grivas, University of Washington; Hamid Emamekhoo, University of Wisconsin Carbone Cancer Center; Prateek Mendiratta, Cleveland Clinic Taussig Center Institute; Siraj Ali, Foundation Medicine; JoAnn Hsu, City of Hope Comprehensive Cancer Center; and Sumanta Pal, City of Hope Comprehensive Cancer Center, also participated in this research.

This study received no specific funding.

Penn State

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...